Carabersat is primarily investigated for its potential therapeutic applications in the treatment of neurological disorders. It has shown promise in preclinical studies as a neuroprotective agent, particularly in conditions involving brain ischemia and stroke. The compound is believed to modulate glutamate release, which plays a critical role in excitotoxicity, a process that leads to neuronal damage. By reducing excessive glutamate activity, it may help protect brain cells from injury and improve outcomes in stroke patients. Additionally, research suggests its potential use in managing other neurodegenerative diseases where glutamate dysregulation is a contributing factor. Further clinical studies are needed to fully establish its efficacy and safety in humans.